NXTC | NextCure, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.2700 - 1.4100
52 Week Range	0.9800 - 2.5700
Beta	1.38
Implied Volatility	394.72%
IV Rank	100.00%
Day's Volume	158,809
Average Volume	47,254
Shares Outstanding	27,975,800
Market Cap	37,207,814
Sector	Healthcare
Industry	Biotechnology
IPO Date	2019-05-09

Valuation
Profitability
Growth
Health
P/E Ratio	-0.61
Forward P/E Ratio	N/A
EPS	-2.19
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	82
Country	USA
Website	NXTC

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.

NXTC's peers: ABIO, ACHL, ACHV, ALGS, ALLK, ASMB, ATHA, BNTC, BOLT, PMCB, BPTH, CAPR, CHRS, CLNN, CLRB, CLSD, CMRX, CNTB, CNTX, CORT, CRBP, CTMX, CYCC, DARE, GLPG, GLSI, KRON, LBPH, LCTX, LVTX, LYRA, MBRX, NKTR, NUVB, SPRO, NLTX, TIL, OVID, PRQR, TBPH, UBX, QNCX, THRD, DOMH

*Chart delayed

Analyzing fundamentals for NXTC we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is weak. For more detailed analysis please see NXTC Fundamentals page.

Watching at NXTC technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on NXTC Technicals page.